|
|
 |
Toremifene (Fareston)® (Toremifene) |
 |
|
|
| Toremifene (Fareston)® |
| Active Ingredient: Toremifene | | Manufacturer: Orion Pharma Finland |
|
Fareston is a novel SERM - Selective Estrogen Receptor Modulator (anti estrogen) that
is supposedly more powerful than Nolvadex and may have less side effects than other anti estrogens.
It also lowers bad cholesterol (LDL) and increase good cholesterol (HDL).
Primarily used to treat breast cancer in post-menopausal women,
it has a great a potential to be used in men as well for various medical conditions.
Since Fareston (Toremifene) has been in market but much less time
than Nolvadex it has fewer medical studies. However due to similarities in action with other SERMs like Nolvadex
though being more potent it has probably even greater potential to treat the same conditions doctors use Nolvadex to treat.
These are extracts from research and studies conducted by various groups and published in
various places. These extracts are for informational purposes only. They should not serve
as a medical advice and do not suggest any self-medicating.
This research suggests Toremifene (Fareston) as an alternative to Nolvadex. The Toremifene (Fareston) group had a greater response than the Tamoxifen (Nolvadex) group did. It also demonstrates the Toremifene group had lower incidence of undesirable effects.
|
Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer.
Breast Cancer research and treatment, January 2001
The Medical Oncology Service, Nuestra Senyora Del Piltar Hospital, Barcelona, Spain.
|
 |
EXTRACT
PURPOSE: Efficacy and safety of toremifene (TOR) 60 mgs/dayly/o.r. was compared with tamoxifen (TAM) 40 mgs/dayly/o.r. in a group of postmenopausal women with advanced breast cancer, without previous systemic therapy for advanced breast cancer. MATERIAL AND METHODS: The study was a prospective double-blind randomized trial. All treated patients presented with positive estrogen receptors. Main end points were response rates, toxicity profile analysis, time to progression and survival. WHO and ECOG criteria were employed for response evaluation while toxicity was assesed according to WHO guidelines. Curves were constructed by means of Kaplan-Meier methodology and were compared by means of log-rank test. RESULTS: From January 1996 to January 1999 a total of 217 patients were included in the study (106 in the TOR branch and 111 in the TAM arm). Both groups of patients were homogeneous regarding the main prognostic factors. A response rate of 64% (68/106) was observed in the TOR group as compared with a 52% (58/111) in the TAM group. Median times to progression and overall survival were not significantly different. A lower incidence of undesirable effects was apreciated in the TOR arm. CONCLUSIONS: Our data suggest that TOREMIFENE (FARESTON) is an efficient and well-tolerated agent for the therapy of postmenopausal women with hormonal positive receptors advanced breast cancer, and must be considered an alternative to TAMOXIFEN (NOLVADEX) as first line therapy for ER+ advanced breast cancer patients and as well as an adjuvant treatment.
|
Toremifene (Fareston) lowered LDL (bad Cholesterol) and increased HDL (good cholesterol) when given to men receiving androgen-deprivation therapy for prostate cancer.
|
Study published in Journal of Clinical Oncology, April 2008
Massachusetts General Hospital Cancer Center
|
|
EXTRACT
EXTRACT: We evaluated the effects of toremifene, a selective estrogen-receptor modulator, on fasting serum lipid levels in men receiving ADT for prostate cancer. PATIENTS AND METHODS: In an ongoing, multicenter, double-blind, placebo-controlled phase III fracture-prevention study, 1,389 men receiving ADT for prostate cancer were randomly assigned to receive toremifene (80 mg/d) or placebo. In this interim analysis of 188 patients, changes in fasting serum lipids from baseline to month 12 were compared between the placebo and toremifene groups. RESULTS: Changes in serum lipids differed significantly between the groups. Mean (+/- SE) total cholesterol decreased by 1.0% +/- 1.7% from baseline to month 12 in the placebo group and decreased by 8.1% +/- 1.4% in the toremifene group (P = .001 for between group comparison). Low-density lipoprotein (LDL) cholesterol increased by 0.8% +/- 2.5% in the placebo group and decreased by 8.2% +/- 2.5% in the toremifene group (P = .003). In contrast, high-density lipoprotein (HDL) cholesterol decreased by 4.9% +/- 1.2% in the placebo group and increased by 0.5% +/- 2.2% in the toremifene group (P = .018). Triglycerides increased by 6.9% +/- 4.2% in the placebo group and decreased by 13.2% +/- 3.6% in the toremifene group (P = .003). CONCLUSION: Toremifene significantly decreased total cholesterol, LDL cholesterol, and triglycerides, and increased HDL cholesterol in men receiving ADT for prostate cancer.
|
Toremifene increases Testosterone, FSH, sperm count and quality in men with fertility problems.
|
Study published in Fertil Steril, October 2007
Aristotle University of Thessaloniki, Thessaloniki, Greece.
|
|
EXTRACT
OBJECTIVE: To evaluate whether toremifene, a selective estrogen receptor modulator (SERM), has a beneficiary effect on all three main sperm parameters. DESIGN: Prospective interventional clinical study. SETTING: University hospital. PATIENT(S): One-hundred subfertile men with idiopathic oligozospermia. INTERVENTION(S): Toremifene (60 mg daily) was administered to all men for 3 months. At baseline and at the end of each month, serum concentrations of follicle-stimulating hormone (FSH), testosterone, inhibin B, and sex hormone-binding globulin (SHBG) were measured. At baseline and at the end, semen analysis was performed and sperm concentration, spermatozoal motility and normal sperm forms were determined. MAIN OUTCOME MEASURE(S): Gonadotropin, testosterone, inhibin-B levels, total sperm count, sperm morphology and motility. RESULT(S): Toremifene administration resulted in a significant increase in FSH, testosterone, SHBG, and inhibin B levels, as well as in sperm concentration, percentage motility and normal sperm forms. Twenty-two men's partners achieved pregnancy within 2 months of the end of treatment. At the end of the third month, serum FSH levels were significantly higher in the men whose partners did not achieve pregnancy, and total sperm count and normal sperm forms were significantly lower compared with the group of men whose partners achieved pregnancy. CONCLUSION(S): Toremifene administration for a period of 3 months in men with idiopathic oligozoospermia is associated with significant improvements of sperm count, motility, and morphology, mediated by increased gonadotropin secretion and possibly a direct beneficial effect of toremifene on the testes. The above findings are also indicative of a better testicular exocrine (improved sperm parameters) response to treatment in men whose partners achieved pregnancy compared with those who did not. Further randomized, placebo-controlled trials should be conducted to determine whether this particular selective estrogen receptor modulator can be useful as an initial approach in men with oligozoospermia.
|
Toremifene (Fareston) increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
|
Study published in Journal of Urology, January 2008
Massachusetts General Hospital, Boston
|
|
EXTRACT
PURPOSE: We evaluated the effects of toremifene on bone mineral density, a surrogate for fracture risk, in men receiving androgen deprivation therapy for prostate cancer. MATERIALS AND METHODS: In an ongoing, multicenter, phase 3 fracture prevention study 1,392 men 50 years or older with prostate cancer receiving androgen deprivation therapy were randomized to 80 mg toremifene per day or placebo. Bone mineral density of the lumbar spine, total hip and femoral neck was assessed using dual energy x-ray absorptiometry. In this planned interim analysis of the first 197 subjects we compared bone mineral density changes from baseline to month 12 between the placebo and toremifene groups. RESULTS: Compared with the placebo group men in the toremifene group had significant increases in bone mineral density at each evaluated skeletal site. Lumbar spine bone mineral density decreased 0.7% in the placebo group and increased 1.6% in the toremifene group (between group comparison p <0.001). Total hip bone mineral density decreased 1.3% in the placebo group and increased 0.7% in the toremifene group (p = 0.001). Femoral neck bone mineral density decreased 1.3% in the placebo group and increased 0.2% in the toremifene group (p = 0.009). Between group differences in the change in bone mineral density from baseline to month 12 were 2.3%, 2.0% and 1.5% for the lumbar spine, total hip and femoral neck, respectively. CONCLUSIONS: Toremifene significantly increased hip and spine bone mineral density in men receiving androgen deprivation therapy for prostate cancer. The effect of toremifene on the fracture risk is being assessed in the ongoing randomized, controlled trial.
|
Toremifene helps in prevention of prostate cancer in men with high grade prostatic intraepithelial neoplasia
|
Study published in Journal of Urology, September 2006
|
|
EXTRACT
PURPOSE: A randomized, double-blind, dose finding, placebo controlled, parallel group clinical study was done to determine the incidence of prostate cancer in men with high grade prostatic intraepithelial neoplasia treated with toremifene. MATERIALS AND METHODS: A total of 514 patients with high grade prostatic intraepithelial neoplasia and no evidence of prostate cancer on screening biopsy were randomized to 20, 40 or 60 mg toremifene, or placebo daily for 12 months. Patients underwent re-biopsy at 6 and 12 months. RESULTS: The number of evaluable patients, that is those with 1 on study biopsy who were compliant, was 447. The cumulative risk of prostate cancer was decreased in patients on 20 mg toremifene compared with placebo (24.4% vs 31.2%, p <0.05). The annualized rate of prevention was 6.8 cancers per 100 men treated. In patients with no biopsy evidence of cancer at baseline and 6 months, the 12-month incidence of prostate cancer was decreased by 48.2% with 20 mg toremifene compared with placebo (9.1% vs 17.4%, p <0.05). The 20 mg dose was most effective but cumulative and 12-month incidences of prostate cancer were lower for each toremifene dose vs placebo with a cumulative risk of 29.2% and 28.1%, and a 12-month incidence of 14.3% and 13.0% for 40 and 60 mg, respectively. Gleason scores were similar across treatments. The overall incidence of drug related and serious adverse events did not differ between any of the toremifene groups and the placebo group. CONCLUSIONS: Toremifene decreased the incidence of prostate cancer by 1 year and had a tolerability profile comparable to that of placebo in a high risk population.
|
These are extracts from research and studies conducted by various groups and published in
various places. These extracts are for informational purposes only. They should not serve
as a medical advice and do not suggest any self-medicating.
Information presented is not medically approved, may be inaccurate and is unreliable. It can not and must not serve as any basis of decision making regarding any health concern or issue.
|
|
 |
|
|
|
|
|
|
 |
|
| Express Shipping |
|
|
Cheap Prices |
|
| U.S. & Worldwide delivery |
|
|
 |
|
|
We ship to U.S., Canada, U.K., Australia & Europe
